食管癌三联治疗后的放射剂量分布与吻合口并发症
回顾性分析51例2007—2014年接受三联治疗的食管癌患者,吻合口漏与狭窄率分别为12%和22%。发生吻合口并发症者食管在奇静脉水平(0.0 cm)及以下(至-2.7 cm)的平均剂量显著更高(28.4-42.2 Gy vs 10.3-27.6 Gy,p<0.04),胃平均剂量无差异;吻合口并发症未影响生存。
要点
- 吻合口漏率12%、狭窄率22%,发生并发症者奇静脉附近食管平均剂量更高(28.4-42.2 Gy vs 10.3-27.6 Gy,p<0.04)。
- 胃平均剂量在有无吻合口并发症者间无差异。
- 吻合口并发症未影响生存,中位随访30.9个月,中位总生存34.4个月、无病生存22.5个月。
核心结论
- 食管癌三联治疗后发生吻合口并发症的患者更可能在奇静脉附近(胸内吻合最常发生处)接受了更高的食管平均剂量。
- 作者认为手术与放射肿瘤科医生就吻合口位置进行沟通,可能是制定三联治疗计划以减少潜在吻合口并发症的重要考虑。
研究设计与样本
- 回顾性分析2007年至2014年间连续51例接受三联治疗的食管癌患者的医疗记录。
- 采用非参数秩和检验分析食管以奇静脉为标志的各区域及胃的平均剂量与吻合口并发症发生的相关性。
主要发现
- 吻合口漏率为12%,吻合口狭窄率为22%。
- 发生吻合口并发症的患者食管在奇静脉水平(0.0 cm)及以下(至-2.7 cm)的平均剂量更高,为28.4-42.2 Gy vs 10.3-27.6 Gy,p<0.04。
- 胃平均剂量未见差异。
- 中位随访时间为30.9个月,中位总生存为34.4个月,中位无病生存为22.5个月。
- 吻合口并发症的发生未影响生存结局。
临床怎么用
- 作者认为手术与放射肿瘤科医生就吻合口位置进行沟通,可能是制定三联治疗计划以减少潜在吻合口并发症的重要考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: There is conflicting evidence with respect to the correlation between neoadjuvant chemoradiation and anastomotic complications following trimodality therapy in patients with esophageal cancer. We aimed to analyze the relationship between their dosimetry and any resulting anastomotic complications. MATERIALS AND METHODS: The medical records of 51 consecutive patients who underwent trimodality therapy between 2007 and 2014 were retrospectively reviewed. We analyzed the differences in the mean dose received by regions of the esophagus relative to the landmark of the azygous vein and the stomach to correlate the development of an anastomotic complication using nonparametric rank-sum tests. RESULTS: Anastomotic leakage and stricture rates were 12% and 22%, respectively. Patients with anastomotic complications received a statistically significant higher mean dose to the esophagus at the level of the azygous vein (0.0 cm) and lower (up to -2.7 cm) (28.4-42.2 Gy vs. 10.3-27.6 Gy, p < 0.04). There were no differences noted in mean gastric doses. Median follow up time was 30.9 months. Median overall survival and disease free survival of our patient cohort was 34.4 months and 22.5 months, respectively. The development of an anastomotic complication did not affect survival outcomes. CONCLUSION: Patients who experienced anastomotic complication after trimodality therapy for esophageal cancer were more likely to have received a higher mean esophageal dose around the proximity of the azygous vein, where intrathoracic anastomoses most commonly occur. Communication between surgical and radiation oncologists regarding the anastomotic location may be an important consideration in planning for trimodality therapy in reducing potential anastomotic complications.
引用
- Bang A, Broomfield JA, Chan J, et al. Radiation dose mapping and anastomotic complications after trimodality therapy for esophageal cancers. Clin Transl Radiat Oncol. 2019. PMID: 30775562. doi:10.1016/j.ctro.2018.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。